Search results for "INFECTIONS"

showing 10 items of 2671 documents

Expansion of the CRF19_cpx Variant in Spain

2015

Abstract Background HIV-1 CRF19_cpx, is a recombinant variant found almost exclusively in Cuba and recently associated to a faster AIDS onset. Infection with this variant leads to higher viral loads and levels of RANTES and CXCR4 co-receptor use. Objectives The goal of this study was to assess the presence of CRF19_cpx in the Spanish province of Valencia, given its high pathogenicity. Study design 1294 HIV-1 protease-reverse transcriptase (PR/RT) sequences were obtained in Valencia (Spain), between 2005 and 2014. After subtyping, the detected CRF19_cpx sequences were aligned with 201 CRF19_cpx and 66 subtype D sequences retrieved from LANL, and subjected to maximum-likelihood phylogenetic a…

Likelihood FunctionsMolecular epidemiologyPhylogenetic treeUnprotected sexBayes TheoremHIV InfectionsBiologyVirologyGroup AHIV Reverse TranscriptaseReverse transcriptaseSubtypingCoalescent theoryPhylogeographyInfectious DiseasesHIV ProteaseSpainVirologyMutationHIV-1HumansRNA ViralViral loadPhylogenyJournal of Clinical Virology
researchProduct

Norovirus in captive lion cub (Panthera leo)

2007

African lions (Panthera leo) are susceptible to viral diseases of domestic carnivores, including feline calici-virus infection. We report the identification of a novel enteric calicivirus, genetically related to human noroviruses of genogroup IV, in a lion cub that died of severe hemorrhagic enteritis.

LionsMicrobiology (medical)GenotypeEpidemiologyanimal diseasesvirusesMolecular Sequence Datalcsh:MedicineDNA FragmentationPanthera leomedicine.disease_causelcsh:Infectious and parasitic diseasesEnteritisFatal Outcomefluids and secretionsSpecies Specificitybiology.animalmedicineAnimalslcsh:RC109-216Amino Acid SequenceFeline calicivirus infectionenteritisPhylogenyCaliciviridae Infectionsbiologylcsh:RNorovirusZoonosisDispatchCaliciviruscalicivirusvirus diseaseszoonosismedicine.diseaseVirologydigestive system diseasesGastroenteritisInfectious DiseasesCaliciviridae InfectionsHemorrhagic enteritisAnimals NewbornDNA ViralNorovirusAnimals ZooPantheraAfrican lion
researchProduct

Adverse drug reactions to antiretroviral medication

2009

Antiretroviral therapy has greatly improved prognosis of HIV infection, with a dramatic reduction of morbidity and mortality worldwide. Nevertheless, the condition is still a common cause of death in many underdeveloped countries, where effective treatment is not always unavailable. More than 20 drugs active against HIV are commercially available, which belong to one of four groups: nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and fusion/entry inhibitors. In the near future new drugs are expected, including those of a novel group, the integrase inhibitors. To avoid viral resistance, combinations of the drugs must always b…

LipodystrophyAnti-HIV Agentsmedicine.medical_treatmentIntegrase inhibitorHIV InfectionsBioinformaticsCardiovascular SystemNervous SystemNucleoside Reverse Transcriptase InhibitorDrug HypersensitivityBone MarrowHumansMedicineEffective treatmentLactic AcidDrug reactionUrinary TractAdverse effectProteasebusiness.industryOsteonecrosisReverse transcriptaseGastrointestinal TractBone Diseases MetabolicLiverPancreatitisAntiretroviral medicationbusinessFrontiers in Bioscience
researchProduct

Different origin of adipogenic stem cells influences the response to antiretroviral drugs

2015

Lipodystrophy (LD) is a main side effect of antiretroviral therapy for HIV infection, and can be provoked by nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs). LD exists in different forms, characterized by fat loss, accumulation, or both, but its pathogenesis is still unclear. In particular, few data exist concerning the effects of antiretroviral drugs on adipocyte differentiation. Adipose tissue can arise either from mesenchymal stem cells (MSCs), that include bone marrow-derived MSCs (hBM-MSCs), or from ectodermal stem cells, that include dental pulp stem cells (hDPSCs). To analyze whether the embryonal origin of adipocytes might impact the occurrence of d…

LipodystrophyPharmacologyBiologyAntiviral Agentschemistry.chemical_compoundFatty acid bindingDental pulp stem cellsLipid dropletAdipocytemedicineAdipocytesReverse transcriptaseAnimalsHumansDental PulpInhibitorsStavudineMesenchymal stem cellMesenchymal Stem CellsCell BiologyProtease inhibitorsVirologyRetroviridaechemistryAdipogenesisAntiretroviral drugsStem cellAntiretroviral drugs; Inhibitors; Lipodystrophy; Protease inhibitors; Reverse transcriptasemedicine.drugRetroviridae Infections
researchProduct

Killed Candida albicans yeasts and hyphae inhibit gamma interferon release by murine natural killer cells.

2006

ABSTRACT Killed yeasts and hyphae of Candida albicans inhibit gamma interferon secretion by highly purified murine NK cells in response to the Toll-like receptor ligands lipopolysaccharide and zymosan. This effect, which is also observed in the presence of NK-activating cytokines (interleukin-2 [IL-2], IL-12, and IL-15), may represent a novel mechanism of immune evasion that contributes to the virulence of C. albicans .

LipopolysaccharidesHyphaLipopolysaccharideImmunologyHyphaeMicrobiologyNatural killer cellMicrobiologychemistry.chemical_compoundInterferon-gammaMiceImmune systemCandida albicansmedicineAnimalsInterferon gammaCandida albicansbiologyInterleukinsZymosanZymosanbiology.organism_classificationCorpus albicansToll-Like Receptor 2Killer Cells NaturalMice Inbred C57BLToll-Like Receptor 4Infectious Diseasesmedicine.anatomical_structurechemistryParasitologyFungal and Parasitic Infectionsmedicine.drugInfection and immunity
researchProduct

Time Response of Oxidative/Nitrosative Stress and Inflammation in LPS-Induced Endotoxaemia—A Comparative Study of Mice and Rats

2017

Sepsis is a severe and multifactorial disease with a high mortality rate. It represents a strong inflammatory response to an infection and is associated with vascular inflammation and oxidative/nitrosative stress. Here, we studied the underlying time responses in the widely used lipopolysaccharide (LPS)-induced endotoxaemia model in mice and rats. LPS (10 mg/kg; from Salmonella Typhosa) was intraperitoneally injected into mice and rats. Animals of every species were divided into five groups and sacrificed at specific points in time (0, 3, 6, 9, 12 h). White blood cells (WBC) decreased significantly in both species after 3 h and partially recovered with time, whereas platelet decrease did no…

LipopolysaccharidesMale0301 basic medicinesepsis; time response; inflammation; oxidative stress; endotoxaemia; mouse; ratLipopolysaccharideNitric Oxide Synthase Type IIBacteremia030204 cardiovascular system & hematologymedicine.disease_causelcsh:ChemistrysepsisendotoxaemiaHemoglobinsLeukocyte CountMicechemistry.chemical_compound0302 clinical medicineoxidative stressratPlateletlcsh:QH301-705.5SpectroscopyGeneral MedicineComputer Science ApplicationsRespiratory burstP-SelectinSalmonella Infectionsmedicine.symptommedicine.medical_specialtyVascular Cell Adhesion Molecule-1InflammationOxidative phosphorylationArticleCatalysisInorganic ChemistrySepsis03 medical and health sciencesSpecies Specificitytime responseInternal medicineReaction TimemedicineAnimalsRats WistarPhysical and Theoretical ChemistryMolecular BiologymouseInterleukin-6Platelet CountTumor Necrosis Factor-alphabusiness.industryOrganic Chemistrymedicine.diseaseRatsMice Inbred C57BL030104 developmental biologyEndocrinologylcsh:Biology (General)lcsh:QD1-999chemistryinflammationImmunologyHemoglobinbusinessOxidative stressInternational Journal of Molecular Sciences
researchProduct

Serum antibodies to Vibrio vulnificus biotype 3 lipopolysaccharide and susceptibility to disease caused by the homologous V. vulnificus biotype

2011

SUMMARYIn 1996 an outbreak of severe soft tissue infections caused byVibrio vulnificusunexpectedly erupted in fish consumers in Israel with relatively little morbidity in fish farmers. To test the hypothesis that recurrent exposure of fishermen to the virulent strain may have provided protection against severe or symptomatic disease, we investigated the association between the immune response toV. vulnificusbiotype 3 lipopolysaccharide (BT3 LPS) and disease susceptibility in fish farmers and fish consumers. Serum samples were tested for IgA and IgG of anti-BT3 LPS in fishermen and fish consumers who suffered fromV. vulnificusBT3 infections and their matched controls. Pre-existing levels of …

LipopolysaccharidesMaleSerumEpidemiologyVirulenceMicrobiologiaVibrio vulnificusImmunoglobulin GSerologyMicrobiologyVibrionaceaeVibrio Infectionsparasitic diseasesHumansIsraelVibrio vulnificusbiologyOutbreakMiddle Agedbiology.organism_classificationAntibodies BacterialImmunoglobulin AInfectious DiseasesCase-Control StudiesImmunoglobulin GVibrio InfectionsImmunologybiology.proteinFemaleDisease SusceptibilityAntibody
researchProduct

Differential uptake and killing potential of Campylobacter jejuni by human peripheral monocytes/macrophages

1997

The ability of Campylobacter jejuni to survive in monocytes after phagocytic uptake was tested in a new in vitro model using adherent macrophages derived from human peripheral monocytes. The cells were stimulated with cytokines before use to ensure full phagocytic and killing activity. The kinetics of uptake and killing of bacteria was followed for 72 h with 16 strains, including stool and blood isolates and laboratory adapted strains. Significant bacterial strain differences were not observed, but the viability of phagocytosed bacteria was dependent on the individual donating the macrophages. The majority of blood donors carried macrophages that killed phagocytosed Campylobacter within 24 …

LipopolysaccharidesMicrobiology (medical)Blood Bactericidal ActivityCellular immunityPhagocytosisImmunologyColony Count MicrobialBacteremiaIn Vitro TechniquesBiologymedicine.disease_causeCampylobacter jejuniMonocytesMicrobiologyCampylobacter jejuniPhagocytosisCampylobacter InfectionsmedicineHumansImmunology and AllergyMacrophagePhosphotransferases (Phosphate Group Acceptor)Superoxide DismutaseMacrophagesMonocyteCampylobacterGeneral MedicineCatalasebiology.organism_classificationEnteritisIn vitroKineticsmedicine.anatomical_structureMutationBacteriaMedical Microbiology and Immunology
researchProduct

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.

2010

It is increasingly clear that a tailored therapeutic approach to patients with hepatitis C virus infection is needed. Success rates in difficult to treat and low-responsive hepatitis C virus patients are not completely satisfactory, and there is the need to optimise treatment duration and intensity in patients with the highest likelihood of response. In addition, the management of special patient categories originally excluded from phase III registration trials needs to be critically re-evaluated. This article reports the recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies.

Liver CirrhosisANTIVIRAL TREATMENTHuman immunodeficiency virus (HIV)HIV InfectionsHepacivirusANTIVIRAL THERAPY; PEGYLATED INTERFERON-ALPHA-2B; LIVER-TRANSPLANTATION; PEGINTERFERON ALPHA-2A; HIV-INFECTED PATIENTS; VIRUS-COINFECTED PATIENTS; RAPID VIROLOGICAL RESPONSEAntiviral therapymedicine.disease_causeGastroenterologyPolyethylene GlycolsHBVguidelinesAcute hepatitisChronic hepatitisSettore MED/12 - Gastroenterologialiver transplantationGastroenterologyAntiviral therapyHepatitis CVIRUS-COINFECTED PATIENTSLIVER-TRANSPLANTATIONHepatitis CRecombinant Proteinsacute hepatitis; antiviral therapy; chronic hepatitis; cirrhosis; elderly patients; hbv; hcv; hdv; hiv; liver transplantationCLINICAL PRACTICE GUIDELINESCirrhosisHCVDrug Therapy CombinationAntiviral therapy Acute hepatitis Chronic hepatitisCirrhosis Elderly patients HBV HCV HDV HIV Liver transplantationElderly patientAcute hepatitiAcute hepatitismedicine.medical_specialtyGenotypePEGINTERFERON ALPHA-2AAlpha interferonHIV-INFECTED PATIENTSInterferon alpha-2CHRONIC HEPATITIS CAntiviral AgentsHepatitis B ChronicChronic hepatitisInternal medicineHDVDrug Resistance ViralRibavirinmedicineHumansPEGYLATED INTERFERON-ALPHA-2BCirrhosiHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAInterferon-alphaHIVHepatitis C Chronicmedicine.diseaseElderly patientsFamily medicineExpert opinionAntiviral therapy; Acute hepatitis; Chronic hepatitis; Cirrhosis; Elderly patients; HBV; HCV; HDV; HIV; liver transplantationChronic hepatitiRAPID VIROLOGICAL RESPONSEbusinessCHRONIC HEPATITIS C; ANTIVIRAL TREATMENT; CLINICAL PRACTICE GUIDELINES
researchProduct

From current status to optimization of HCV treatment: Recommendations from an expert panel

2016

Chronic hepatitis C virus (HCV) infection is a major public health problem at a global level, causing an enormous burden of hepatic and extra-hepatic morbidity and mortality. Treatment of chronic HCV (CHC) has been revolutionized in the last few years by the introduction of highly effective and well tolerated direct acting antiviral agents (DAAs) able to achieve >90% rates of sustained virological response (SVR) in many groups of patients, including those previously excluded from interferon-based regimens. For such reason interferon-free regimens are now the treatments of choice for all patients. Successful anti-HCV treatment can stop liver disease progression and can solve the HCV-relat…

Liver CirrhosisDirect-acting antiviral agentmedicine.medical_treatmentResistanceAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Antiviral Agents; Carcinoma Hepatocellular; Coinfection; Drug Therapy Combination; HIV Infections; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies Medical; Viral Load; Hepatology; GastroenterologyHIV InfectionsHepacivirusAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Hepatology; GastroenterologyLiver transplantationAntiviral therapyLiver disease0302 clinical medicineHIV Infection030212 general & internal medicineChronicSocieties MedicalCoinfectionLiver NeoplasmsGastroenterologyHepatitis CViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCirrhosisLiver NeoplasmCombinationPractice Guidelines as TopicHCV030211 gastroenterology & hepatologyDrug Therapy CombinationViral loadHumanAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistancemedicine.medical_specialtyCarcinoma HepatocellularLiver CirrhosiAlpha interferonAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Antiviral Agents; Carcinoma Hepatocellular; Coinfection; Drug Therapy Combination; HIV Infections; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies Medical; Viral LoadAntiviral Agents03 medical and health sciencesDrug TherapyMedicalInternal medicineRibavirinmedicineHumansIntensive care medicineAntiviral AgentCirrhosiHepaciviruLiver transplantationHepatologybusiness.industryPublic healthCarcinomaInterferon-alphaHepatocellularHepatologyHepatitis C Chronicmedicine.diseaseSurgeryPosition paperDirect-acting antiviral agentsSocietiesbusiness
researchProduct